These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 15992916

  • 1. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    O'Malley DM, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M, Schwartz P, Rutherford T.
    Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
    [Abstract] [Full Text] [Related]

  • 2. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC.
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M, Safra T.
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
    Miller DS, Blessing JA, Lentz SS, McMeekin DS.
    Cancer; 2003 Oct 15; 98(8):1664-9. PubMed ID: 14534883
    [Abstract] [Full Text] [Related]

  • 8. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
    Spannuth WA, Leath CA, Huh WK, Barnes MN, Davidson SA, Kilgore LC, Partridge EE, Austin JM, Alvarez RD.
    Gynecol Oncol; 2007 Mar 15; 104(3):591-5. PubMed ID: 17045635
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B, Hansen HH, Høgdall C, Engelholm SA.
    Cancer; 2002 Oct 15; 95(8):1656-62. PubMed ID: 12365013
    [Abstract] [Full Text] [Related]

  • 10. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
    Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP.
    Gynecol Oncol; 2000 Dec 15; 79(3):495-8. PubMed ID: 11104627
    [Abstract] [Full Text] [Related]

  • 11. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG.
    Gynecol Oncol; 2006 Nov 15; 103(2):637-41. PubMed ID: 16781766
    [Abstract] [Full Text] [Related]

  • 12. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [Abstract] [Full Text] [Related]

  • 13. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Gynecol Oncol; 2000 Oct 15; 79(1):116-9. PubMed ID: 11006042
    [Abstract] [Full Text] [Related]

  • 14. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
    Denschlag D, Watermann D, Hörig K, Kissel C, Tempfer C, Gitsch G.
    Anticancer Res; 2004 Oct 15; 24(2C):1267-9. PubMed ID: 15154658
    [Abstract] [Full Text] [Related]

  • 15. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ.
    Gynecol Oncol; 1997 Sep 15; 66(3):480-6. PubMed ID: 9299264
    [Abstract] [Full Text] [Related]

  • 16. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.
    Hanjani P, Nolte S, Shahin MS.
    Gynecol Oncol; 2002 May 15; 85(2):278-84. PubMed ID: 11972388
    [Abstract] [Full Text] [Related]

  • 17. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG, Gordon NH, Fusco N, Fluellen L, Rodriguez M, Ingalls ST, Hoppel CL.
    Gynecol Oncol; 2000 Aug 15; 78(2):228-34. PubMed ID: 10926808
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J, Holloway R, Ndubisi B, Orr J, Grendys E, Boothby R, DeCesare S, LaPolla J, Hoffman M, Patel J.
    Gynecol Oncol; 2002 Apr 15; 85(1):89-94. PubMed ID: 11925125
    [Abstract] [Full Text] [Related]

  • 19. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG.
    Gynecol Oncol; 2009 Aug 15; 114(2):210-4. PubMed ID: 19446320
    [Abstract] [Full Text] [Related]

  • 20. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
    Rose PG, Smrekar M, Haba P, Visser C, Beeler JF.
    Gynecol Oncol; 2005 Dec 15; 99(3):714-9. PubMed ID: 16112177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.